Report of the Fifth Post-Kala-Azar Dermal Leishmaniasis Consortium Meeting, Colombo, Sri Lanka, 14-16 May 2018

Eduard E Zijlstra; Amresh Kumar; Abhijit Sharma; Suman Rijal; Dinesh Mondal; Satyabrata Routray

doi:10.1186/s13071-020-04011-7

Report of the Fifth Post-Kala-Azar Dermal Leishmaniasis Consortium Meeting, Colombo, Sri Lanka, 14-16 May 2018

Parasit Vectors. 2020 Mar 30;13(1):159. doi: 10.1186/s13071-020-04011-7.

Authors

Eduard E Zijlstra¹, Amresh Kumar², Abhijit Sharma², Suman Rijal³, Dinesh Mondal⁴, Satyabrata Routray²

Affiliations

¹ Drugs for Neglected Diseases Initiative, 15 Chemin Louis Dunant, 1202, Geneva, Switzerland. ezijlstra@dndi.org.
² PATH, 15th Floor, Dr. Gopaldas Building, 28 Barakhamba Road, Connaught Place, New Delhi, 110001, India.
³ Drugs for Neglected Diseases Initiative, PHD House, 3rd Floor, 4/2 Siri Institutional Area, New Delhi, 110016, India.
⁴ Nutrition and Clinical Services Division, International Center For Diarrheal Disease Research, Bangladesh (icddr,b), 63 Shaheed Taj Uddin Ahmed Sarani, Mohakhali, Dhaka, Bangladesh.

Abstract

The 5th Post-Kala-Azar Dermal Leishmaniasis (PKDL) Consortium meeting brought together PKDL experts from all endemic areas to review and discuss existing and new data on PKDL. This report summarizes the presentations and discussions and provides the overall conclusions and recommendations.

Keywords: Diagnosis; Epidemiology; Immunology; Parasitology; Post-kala-azar dermal leishmaniasis; Recommendations; Treatment.

MeSH terms

Animals
Humans
Kinetics
Leishmaniasis Vaccines
Leishmaniasis, Cutaneous
Leishmaniasis, Visceral / diagnosis*
Leishmaniasis, Visceral / epidemiology*
Leishmaniasis, Visceral / immunology
Leishmaniasis, Visceral / therapy
Sri Lanka / epidemiology
Xenodiagnosis

Substances

Leishmaniasis Vaccines